Source-grounded facts extracted from NEPHROS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
NEPHROS INC reported first quarter ended March 31, 2026 results: revenue $5.2 million, net income $140,000.
“Net revenue was $5.2 million, compared to $4.9 million in the first quarter of 2025, up 7% ● Net income was $140,000, compared to a net income of $558,000 in the first quarter of 2025”
NEPHROS INC terminated Prior Agreement with Medica S.p.A. (effective 2025-11-21).
“The License and Supply Agreement supersedes and replaces that certain License and Supply Agreement, dated December 11, 2023 (the “Prior Agreement”), between the Company and Medica, which Prior Agreement was terminated by the parties upon entry into the License and Supply Agreement.”
NEPHROS INC entered into License and Supply Agreement with Medica S.p.A. valued at minimum annual aggregate purchases from Medica of €4,976,000, €5,349,000, €5,750,000, €6,000,000 and (effective 2025-11-21).
“On November 21, 2025, Nephros, Inc. (the “Company”) entered into a license and supply agreement (the “License and Supply Agreement”) with Medica S.p.A. (“Medica”), an Italy-based medical product manufacturing company, for the marketing and sale of certain filtration products based upon Medica’s proprietary Medisulfone ultrafiltration technology in conjunction with the Company’s filtration products (collectively, the “Products”), and to engage in an exclusive supply arrangement for the Products.”
Alisa Lask departed as Director at NEPHROS INC.
“On April 23, 2025, Alisa Lask notified the Board of Directors (the “Board”) of Nephros, Inc. (the “Company”) that she will not stand for re-election to the Board at the Company’s annual meeting of stockholders scheduled to be held on June 16, 2025 (the “2025 Annual Meeting”).”
NEPHROS INC reported first quarter ended March 31, 2024 results: revenue $3.5 million, net income Net loss of $0.2 million.
“Nephros Announces Financial Results for Quarter Ended March 31, 2024 First-Quarter Net Revenue of $3.5 Million”
NEPHROS INC reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue Net revenue from continuing operations was $14.2 million, net income Net loss from continuing operations was ($1.6 million).
“Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.3 Million”
Andrew Astor resigned as Chief Financial Officer at NEPHROS INC.
“On November 1, 2023, in connection with Ms. Krandel’s appointment as Chief Financial Officer, Andrew Astor resigned as the Company’s Chief Financial Officer.”
Judy Krandel was appointed as Chief Financial Officer at NEPHROS INC.
“Nephros, Inc. (the “Company”) appointed Judy Krandel as its Chief Financial Officer, effective November 1, 2023.”
NEPHROS INC reported the second quarter ended June 30, 2023 results: revenue $3.5 million, net income $0.4 million.
“Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South 201 343 5202 nephros.com Nephros Announces Results for Quarter Ended June 30, 2023 Second-Quarter Net Revenue of $3.5 Million, a 24% Increase Over 2022; Year-to-Date Revenue Increases 45%; Maintains Positive Cash Flow Results SOUTH ORANGE, NJ, August 9, 2023 – Nephros, Inc. (Nasdaq: NEPH), a leading”
NEPHROS INC shareholders approved Approval of the compensation of the Company’s named executive officers on an advisory (non-binding) basis at the 2023-06-01 meeting.
“Stockholders approved the compensation of the Company’s named executive officers on an advisory (non-binding) basis”
NEPHROS INC shareholders approved Ratification of the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-01 meeting.
“Stockholders ratified the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023”
NEPHROS INC shareholders approved Election of Director at the 2023-06-01 meeting.
“Stockholders elected to the Company’s Board of Directors one nominee, Joseph Harris, to serve a three-year term expiring in 2026”
Andrew Astor resigned as President and Chief Executive Officer at NEPHROS INC.
“On May 5, 2023, Andrew Astor resigned as the Company’s President and Chief Executive Officer and from the Company’s Board of Directors, effective as of the Effective Date.”
Robert Banks was appointed as Director at NEPHROS INC.
“Mr. Banks was also appointed to the Company’s Board of Directors as a Class III director as of the Effective Date.”
Robert Banks was appointed as President and Chief Executive Officer at NEPHROS INC.
“On May 5, 2023, Nephros, Inc. (the “Company”) entered into an employment agreement with Robert Banks (the “Employment Agreement”) pursuant to which the Company appointed Mr. Banks as its President and Chief Executive Officer”
NEPHROS INC reported the quarter ended March 31, 2023 results: revenue approximately $3.7 million.
“Nephros Announces Preliminary Results for First Quarter 2023 Net Revenue of $3.7 Million, a 69% Year-Over-Year Increase”
NEPHROS INC reported fourth quarter and fiscal year ended December 31, 2022 results: revenue $2.6 million (Q4); $10.0 million (FY), net income ($0.7 million) (Q4); ($4.3 million) (FY).
“Nephros Announces Fourth Quarter and Fiscal Year 2022 Financial Results Full-Year Net Revenue of $10 Million and Fourth Quarter Net Revenue of $2.6 Million”
Alisa Lask was appointed as Member of Audit Committee at NEPHROS INC.
“On February 2, 2023, the Company’s Board of Directors appointed Alisa Lask to serve as a member of its Audit Committee, filling the vacancy created by Mr. Gwydir’s resignation.”
Thomas Gwydir resigned as Director at NEPHROS INC.
“On January 30, 2023, Thomas Gwydir resigned from the Board of Directors of Nephros, Inc. (the “Company”), effective February 1, 2023.”
NEPHROS INC reported fiscal year ended December 31, 2022 results: revenue approximately $10.0 million.
“Full-year 2022 net revenue is expected to be approximately $10.0 million”
NEPHROS INC reported fourth quarter ended December 31, 2022 results: revenue approximately $2.6 million.
“Net revenue for the quarter ended December 31, 2022 is expected to be approximately $2.6 million”
NEPHROS INC completed a disposition involving BWSI, LLC for BWSI made a nominal cash payment and assumed certain liabilities of the PDS Business from and after the date of Closing. Additionally, the Purchase Agreement pr (closed 2022-11-15).
“As previously disclosed, on October 4, 2022, Nephros, Inc. (the “Company”) entered into an Agreement for Purchase and Sale of Assets (the “Purchase Agreement”) with BWSI, LLC (“BWSI”), pursuant to which the Company agreed to sell, and BWSI agreed to purchase, substantially all of the assets relating to the Company’s Pathogen Detection Systems line of business (the “PDS Business”). The parties consummated the transactions contemplated by the Purchase Agreement at a closing conducted on November 15, 2022.”
NEPHROS INC reported the third quarter ended September 30, 2022 results: revenue $2.4 million, net income $1.3 million.
“Net revenue from continuing operations for the quarter ended September 30, 2022, was $2.4 million, compared to $2.6 million in the corresponding period in 2021, a decrease of 7%. Net loss from continuing operations for the quarter ended September 30, 2022, was $1.3 million, compared to $0.8 million during the same period in 2021.”
Joseph Harris was appointed as Class III Director at NEPHROS INC.
“appointed Joseph Harris as a director of the Company.”
Wes Lobo resigned as Chief Commercial Officer at NEPHROS INC.
“On August 17, 2022, Wes Lobo, Chief Commercial Officer of Nephros, Inc. (the “Company”), notified the Company that he is resigning his employment with the Company, to be effective no later than September 30, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.